TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04228848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: new triple hop test
Description: New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
Study: NCT00862095

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every month for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: target does 80 mg per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Target does of 50 mg per day for 3 months
Study: NCT01293071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic rotation
Description: Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic rotation
Description: Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
Study: NCT01697280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine promotion messages
Description: The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine promotion messages
Description: The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccination Verification.
Description: EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccination Verification.
Description: EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
Study: NCT00862095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Target dose 100 mg a day for 3 months
Study: NCT00796588

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: remote preconditioning
Description: Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet

Intervention type: OTHER
Group type: OTHER
Intervention: remote preconditioning
Description: Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
Study: NCT04152382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3462817 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3462817 - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02652039

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires
Study: NCT01370460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical tranexamic acid (2g/100mL 0.9% saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL 0.9% sterile saline
Study: NCT01438008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% sucrose po solution
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo po
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure
Study: NCT02912273

Intervention type: OTHER
Intervention: Baseline Participant Assessment
Description: * Section 1 contains demographic questions~* Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~* Section 3 has the participant list all medication~* Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~* Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~* Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling
Study: NCT01697280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution of Plastic Pouches to retain vaccination card
Description: At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
Study: NCT02071433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous nerve blockade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve blockade
Study: NCT01457183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed lavage (Stryker Pulsavac Plus)
Description: Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
Study: NCT02437136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)
Study: NCT02823158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)
Description: Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Patients will receive optimized medical treatment according to published evidence based guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Patients will receive optimized medical treatment according to published evidence based guidelines.
Study: NCT02399033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xihuang Capsules
Description: In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
Study: NCT03664128

Intervention type: OTHER
Intervention: Coping with Anxiety through Living Mindfully (CALM) Pregnancy
Description: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
Study: NCT03162679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills training of Affect-Regulation - A culture-sensitive approach: STARK
Description: Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
Study: NCT02368327

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02846103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples
Study: NCT01110252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cells stimulation
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells stimulation
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells collection
Description: pullout of 200ml of bone marrow through the puncture of the iliac crest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells collection
Description: pullout of 200ml of bone marrow through the puncture of the iliac crest

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: stem cells infusion
Description: slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: stem cells infusion
Description: slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
Study: NCT00895830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD405
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD405
Description: IV
Study: NCT01697280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution of Plastic Pouches to retain vaccination card
Description: At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution of Plastic Pouches to retain vaccination card
Description: At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
Study: NCT01547559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:teprenone
Description: Teprenone 50mg tid after meal for Hp negative patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:EAC-T
Description: esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:EA-EMC-T
Description: esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: part1:teprenone
Description: Teprenone 50mg tid after meal for Hp positive patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part2:GGA group
Description: GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
Study: NCT00895830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD405
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD405
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT04144439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GABA
Description: Gamma amino butyric acid
Study: NCT00382031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zalutumumab
Description: Individual dose titration weekly i.v doses

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best Supportive Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Best Supportive Care
Study: NCT00808041

Intervention type: DEVICE
Intervention: Dedicated breast computed tomography imaging
Description: Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
Study: NCT01811147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Description: Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Description: Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
Study: NCT04863274

Intervention type: DRUG
Intervention: atorvastatin
Description: Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre.
Study: NCT03791333

Intervention type: OTHER
Intervention: injury severity score
Description: injury severity score of multi trauma patients
Study: NCT04663945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biobehavioral Tele-rehabilitation Sessions
Description: Biobehavioral tele-rehabilitation sessions
Study: NCT02630160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Intraarticular infusion with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Intraarticular infusion with bupivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Saline
Description: Intraarticular infusion physiological serum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Saline
Description: Intraarticular infusion physiological serum
Study: NCT04007315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboGlove therapy
Description: An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 6-weeks of usual NHS care
Study: NCT00565331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study: NCT01976806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Docosahexaenoic acid)
Description: Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
Study: NCT01106040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
Study: NCT04093596

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-715
Description: ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
Study: NCT01274884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tightrope fixation
Description: Arthroscopic repair
Study: NCT02445547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-MSCs by peripheral intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: received hormone maintenance therapy
Study: NCT02506933

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03977246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-placebo
Description: Application of the open-placebo intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Application of the control session
Study: NCT02506933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study: NCT00508573

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Follow-up questionnaire done once a year for five years.
Study: NCT05124223

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI was performed as clinically indicated to assess cardiac pathology.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
Study: NCT04630379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Visit with palliative care team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Visit with palliative care team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Visit with neuro-oncologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Visit with neuro-oncologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Visit with neuro-oncologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey
Study: NCT01722513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil ﹠control
Description: control:Normal salin 1cc/kg/hr before and after angiography